The Ottawa Neuromuscular Centre at The Ottawa Hospital is a leading clinical research centre established to improve the diagnosis and care, as well as develop innovative therapies for adults with neuromuscular diseases (NMD).
We are committed to improving the health of patients with neuromuscular diseases by providing comprehensive care, offering leading clinical trials, and developing novel investigator-led research.
We also collaborate with world-renowned basic scientists to increase understanding of rare neuromuscular diseases and hope to translate this research from the laboratory to advance treatments and provide faster diagnoses for our patients.
Together, we hope that our dedication to compassionate care and the pursuit of evidence-based medicine will improve patients’ lives.
We accept referrals for patients with:
Motor neuron diseases (amyotrophic lateral sclerosis, spinal muscular atrophy)
Neuropathies (diabetic polyneuropathy, Charcot-Marie-Tooth disease, mononeuropathies, and chronic inflammatory demyelinating polyneuropathy CIDP)
Myasthenic disorders (myasthenia gravis, congenital myasthenic syndromes)
Muscle diseases (muscular dystrophy, auto-immune myopathies) and more.
WHAT WE OFFER
NEXT LEVEL CLINICAL CARE
Over 10,000 people are affected by neuromuscular disorders in the Ottawa region. Many of these disorders require a high level of expertise and the latest medical technology to diagnose.
CUTTING-EDGE DIAGNOSTIC TECHNOLOGY
With state-of-the-art clinical trial facilities and advanced diagnostic facilities, our certified technologists are experts in Electromyography (EMG), nerve conduction study, and more.
We also use advanced muscle and nerve ultrasound, needle biopsies for minimally invasive diagnostic techniques.
EXCITING RESEARCH OPPORTUNITIES
Many neuromuscular disorders currently remain untreatable, however, there have been recent exciting discoveries that may translate to better diagnosis and therapies for patients with rare diseases.
At the Neuromuscular Centre, we create opportunities for people to participate in clinical trials, right here in our nation's capital.
Partnered with the University of Ottawa, the Éric Poulin Centre for Neuromuscular Disease, the Children’s Hospital of Eastern Ontario Research Institute, and innovative pharmaceutical companies, we test and develop new medications for neuromuscular diseases.
Our goal is to use our medical discoveries to understand the nature of rare diseases and help to develop new therapies for patients with neuromuscular disorders.
National Spinal Muscular Atrophy Registry for Real-World Evidence.
Spinal muscular atrophy (SMA) is a devastating rare disease that affects individuals regardless of ethnicity, gender, and age. The first-approved disease-modifying therapy for SMA, nusinursen, was approved by Health Canada, as well as by American and European regulatory agencies following positive clinical trial outcomes. The trials were conducted in a narrow pediatric population defined by age, severity, and genotype. Broad approval of therapy necessitates close follow-up of potential rare adverse events and effectiveness in the larger real-world population.